Should I start colorectal cancer screening at 45?

Share This Post

A new study reported at the European Digestive Disease Week (UEG) shows that regardless of family history, colorectal cancer screening has doubled since the age of 45 rather than 50. (UEG 2017)

The researchers pointed out that the general population of the colonoscopy screening program recommends screening for people over the age of 50, but the incidence of colorectal cancer under the age of 50 has increased.

This prospective study evaluated 6027 cases of colonoscopy. The detection rates of polyps, adenomas, large polyps and cancer were 34.0%, 32.0%, 8.0% and 3.6%, respectively. One of the more important findings of this study is that when the risk of adenoma and cancer detection is analyzed by different age groups, the detection rate of people under 30 years old is very low, and it is relatively low before 45 years old. There is a very significant increase.

The average polyp detection rate of 4438 patients over 50 years old was over 35%, and the cancer detection rate exceeded 5%. The average polyps detection rate of 515 patients aged 45-49 years was 26%, and the cancer detection rate was nearly 4%. The detection rate of 1076 subjects ≤44 years old was very low. Even after excluding high-risk populations with a family history, the detection rate of polyps or cancer was still high among people aged 45 to 49 years.

The researchers believe that the research population is a real practice population, so the research conclusions are applicable to the general screening population. 50-year-old should not be used as the starting age for screening, and colorectal cancer screening should be started from 45-year-old to better prevent colorectal cancer. The results of the study suggest that, even if there is no family history, the risk of disease will increase greatly after the age of 45, which is more critical. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy